Dual GIP/GLP-1 Drug Survodutide Cuts Weight in Diabetic Obesity but Tolerability Lags

A new investigational drug targeting two key metabolic hormones showed real but imperfect results in people living with both type 2 diabetes and obesity, according to phase III data presented at the European Association for the Study of Diabetes annual meeting in Milan and simultaneously published in the New England Journal of Medicine.

Survodutide, a dual agonist of the GIP and GLP-1 receptors, was tested in the SYNCHRONIZE-2 trial across two doses — 3.6 mg and 6 mg — against placebo over 76 weeks. Patients on the 6 mg dose lost an average of 9.8% of their body weight, while those on 3.6 mg lost 8.2%, compared to 3.9% in the placebo group. More than 64% of participants in the high-dose group achieved the clinically meaningful threshold of at least 5% weight loss. HbA1c levels also dropped, and improvements in systolic blood pressure, waist circumference, and lipids were recorded — a cluster of cardiometabolic gains directly relevant to reducing long-term disease risk and extending healthspan.

Despite these benefits, the trial exposed a substantial tolerability problem. Between 73% and 78% of survodutide-treated patients experienced gastrointestinal side effects, and 26% discontinued treatment due to adverse events — dramatically higher than the roughly 2–5% discontinuation rates seen with competing agents such as semaglutide or retatrutide. Researchers and commentators have pointed to the drug's rigid six-step, 24-week dose-escalation schedule as a likely contributor to this dropout burden.

Notably, weight loss in SYNCHRONIZE-2 was lower than the 13% achieved in SYNCHRONIZE-1, which enrolled people without diabetes — a gap consistent with the known blunting of GLP-1 efficacy in the diabetic metabolic environment.

Developer Boehringer Ingelheim has acknowledged the issue and plans future trials with more patient-centered, flexible titration approaches. Until tolerability is solved, survodutide's real-world potential remains constrained, even if its mechanism is scientifically compelling for metabolic aging and cardiovascular risk reduction.